41 completed, 10 active not recruiting, 9 unknown, 7 terminated. 26 Phase 2, 22 Phase 1, 16 Phase 3, 8 Not applicable, 5 Phase 4.
Follow BCG: new trials by email Literature Review of BCG trials Research Report on BCG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Role of Definitive Radiotherapy in Non Muscle Invasive Bladder Cancer Definitive radiotherapy, BCG, Concurrent chemotherapy - Non Muscle Invasive Bladder Cancer | Not applicable | Not yet recruiting | Assiut University | 70 | 2026-10-02 | 2026-10-14 |
| Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia Bacillus Calmette Guerin Vaccine, Saline Injection - Fibromyalgia | Phase 2 | Withdrawn | Massachusetts General Hospital | 2026-01-01 | 2024-11-21 | |
| A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer. radiotherapy, BCG - High-Risk Non-Muscle Invasive Bladder Cancer | Phase 3 | Not yet recruiting | The Christie NHS Foundation Trust | 328 | 2025-12-01 | 2025-12-05 |
| A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer PF-08052667, Sasanlimab, BCG - Non-muscle Invasive Bladder Cancer | Phase 1 | Recruiting | Pfizer | 294 | 2025-11-06 | 2026-10-13 |
| Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer N-803 and BCG, N-803 and Gemcitabine - Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 20 | 2025-11-01 | 2025-10-16 |
| A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) Intismeran autogene, BCG - Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 308 | 2025-03-11 | 2026-10-01 |
| First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b H107e, CAF®10b, H107e/CAF®10b - low adjuvant dose - Healthy | Phase 1 | Active not recruiting | Statens Serum Institut | 140 | 2024-03-14 | 2026-03-10 |
| A Controlled Human Infection Model (CHIM) With Intradermal BCG in Malawi BCG - Tuberculosis | Not applicable | Unknown | Liverpool School of Tropical Medicine | 30 | 2024-03-01 | 2023-12-21 |
| Evaluating the Safety and Immunogenicity of MTBVAC MTBVAC, BCG - HIV I Infection, Tuberculosis | Phase 2 | Recruiting | HIV Vaccine Trials Network | 276 | 2024-01-30 | 2026-10-30 |
| Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC) BCG for Therapeutic Use - Non-Muscle Invasive Bladder Cancer | Phase 3 | Unknown | Chengdu CoenBiotech Co., Ltd | 412 | 2023-12-28 | 2024-02-05 |
| Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer Disitamab vedotin, Bacillus Calmette Guerin Vaccine - Non-muscle Invasive Bladder Cancer, HER-2 Protein Overexpression | Phase 2 | Active not recruiting | Fudan University | 20 | 2023-12-18 | 2026-07-20 |
| BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants Durvalumab, BCG - Non-Muscle- Invasive Bladder Cancer | Phase 3 | Active not recruiting | AstraZeneca | 100 | 2023-08-11 | 2026-08-13 |
| Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years Bacillus Calmette-Guérin, Saline Injection - Diabetes Mellitus, Type 1 Diabetes | Phase 2 | Active not recruiting | Massachusetts General Hospital | 100 | 2023-05-04 | 2026-06-26 |
| Intravesical BCG vs GEMDOCE in NMIBC Gemcitabine, Docetaxel, Bacillus Calmette Guerin - Non-muscle-invasive Bladder Cancer | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 870 | 2023-02-07 | 2026-09-15 |
| Coadministration of GA2 Sporozoites With Adjuvants GA2, BCG, YF-17D (fractional ID dose) - Malaria,Falciparum | Early Phase 1 | Unknown | Leiden University Medical Center | 45 | 2023-02-03 | 2023-02-10 |
| Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines BCG Vaccine USP, Isoniazid, Rifampin - Tuberculosis | Phase 1 | Completed | Fred Hutchinson Cancer Center | 20 | 2022-12-06 | 2025-12-16 |
| Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC) BCG for Therapeutic Use - Non-muscular Invasive Bladder Cancer | Phase 1 | Completed | Chengdu CoenBiotech Co., Ltd | 10 | 2022-11-11 | 2024-04-05 |
| Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa MTBVAC, BCG - Tuberculosis | Phase 3 | Recruiting | Biofabri, S.L | 7120 | 2022-10-17 | 2025-02-10 |
| Long Term Effects of BCG Vaccination on Infectious and Immune Mediated Diseases BCG, Placebo vaccine - BCG Vaccination Reaction, Infections | Active not recruiting | Radboud University Medical Center | 4292 | 2022-05-20 | 2025-04-20 | |
| Machine Learning-Based Prediction of BCG Response in High-Risk Non-Muscle Invasive Bladder Cancer Patients Bacillus Calmette-Guerin - Non-Muscle Invasive Bladder Cancer | Unknown | Mansoura University | 100 | 2022-04-01 | 2022-04-18 |
Showing 20 of 77. Sign in to see all of them.
Tuberculosis (24) · Urinary Bladder Neoplasms (21) · Non-Muscle Invasive Bladder Neoplasms (18) · Diabetes Mellitus (3) · Diabetes Mellitus, Type 1 (3) · Infections (3) · Neoplasms (3) · COVID-19 (2) · Hypersensitivity (2) · Malaria (2) · Malaria, Falciparum (2) · Neoplasms by Site (2) · Urinary Bladder Diseases (2) · Urologic Diseases (2) · Urologic Neoplasms (2)
University of Oxford (5) · Aeras (4) · Massachusetts General Hospital (4) · Biofabri, S.L (3) · Radboud University Medical Center (3) · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (2) · Bandim Health Project (2) · Chengdu CoenBiotech Co., Ltd (2) · London School of Hygiene and Tropical Medicine (2) · Medical Enterprises Europe B.V. (2) · Merck Sharp & Dohme LLC (2) · Pfizer (2) · Serum Life Science Europe GmbH (2) · The University of Texas Health Science Center at San Antonio (2) · University of Campinas, Brazil (2)
United States (20) · United Kingdom (12) · South Africa (10) · Netherlands (9) · China (7) · Spain (7) · Australia (6) · Brazil (6) · France (6) · Italy (6) · Canada (4) · Germany (4) · Greece (4) · Belgium (3) · Guinea-Bissau (3)
Denise L Faustman, MD, PhD (2) · Helen McShane (2) · Leonardo O Reis, MD, PhD (2) · Mark Hatherill (2) · Michele Tameris, MD (2) · Wei Lu, Master (2) · Alfred A Witjes, MD PhD (1) · Alicia Hsin-Ming Chang (1) · Amabelia Rodrigues, PhD (1) · Angelique Luabeya, MD (1) · Ann M. Ginsberg, MD, PhD (1) · Antonios Papadopoulos, MD, PhD (1)
PMID 15502839, PMID 16389183, PMID 19529780, PMID 2265339, PMID 22905105, PMID 23290835, PMID 25108027, PMID 25123116, PMID 26048780, PMID 26259542, PMID 26803476, PMID 26845426, PMID 27974398, PMID 28405623, PMID 28498853, PMID 29432383, PMID 29552014, PMID 29685114, PMID 29915522, PMID 29996082, PMID 30791143, PMID 31120957, PMID 31416768, PMID 31843845, PMID 32065303, PMID 32162533, PMID 32382714, PMID 32544459, PMID 32941801, PMID 32978212, PMID 34021314, PMID 34309859, PMID 35170523, PMID 35599154, PMID 35738969, PMID 35772447, PMID 37400353, PMID 37743116, PMID 38189180, PMID 38328938, PMID 38621405, PMID 39004434, PMID 39423450, PMID 39752894, PMID 39753962, PMID 40101388, PMID 40450141, PMID 40464744, PMID 41047269, PMID 41436847
2017 (2), 2018 (1), 2019 (1), 2023 (1), U10CA180820 (1)